|
Plenary session 1: Opening ceremony
L1.1 NDDO Honorary Award Lecture 2012: Miles to go before we sleep: Fifteen years of targeted therapy development and the path ahead. Elizabeth Eisenhauer, Kingston, ON, Canada
L1.2 Keynote Lecture: Challenges in translating success from the lab to the clinic: A perspective on our current infrastructure and suggestions on ways to improve it. Lee Ellis, Houston, TX, USA.
Plenary session 2: Phase 1 studies, completed or in progress
L2.1 PI3K pathway inhibitors: How deep should we go? Josep Tabernero, Barcelona, Spain
L2.2 The evolution of PI3 kinase inhibitors: Results of a first-in-human Phase I study of BAY 80-6946 in patients with advanced solid tumors. Amita Patnaik, San Antonio, TX, USA
L2.3 A phase 1 study of LY2584702, a p70S6 kinase inhibitor, with erlotinib or everolimus in patient with advanced solid tumors. Antoine Hollebecque, Villejuif, France
L2.4 A phase 1 dose-escalation, pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of oral LY2584702 a p70S6 kinase inhibitor. Karim Benhadji, Indianapolis, IN, USA (slides not available)
L2.5 First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors. Jean Charles Soria, Villejuif, France
Plenary session 3: New technologies and models in drug discovery and development
L3.1 Drugging chromosome instability to target cancer. René Medema, Amsterdam, The Netherlands
L3.2 Genomics in drug discovery and development. Aled Edwards, Toronto, ON, Canada
L3.3 The Cancer Genome Atlas: How is it facilitating drug development? Ramaswamy Govindan, St Louis, MO, USA (slides not available)
L3.4 Patient-derived tumor xenograft models: The next generation of preclinical models for oncology drug development. Gail Eckhardt, Aurora, CO, USA
L3.5 Studying therapy response and resistance in mouse models of BRCA-associated breast cancer. Jos Jonkers, Amsterdam, The Netherlands (slides not available)
L3.6 NBTXR3 nanoparticles for radioenhancement: Rationale for the first- in-man study in advanced soft tissue sarcoma. Alain Herrera, Paris, France
Plenary session 4: Stem cells and cancer stem cells
L4.1 Targeting cancer stem cells in solid tumors. Ruggero De Maria, Rome, Italy
L4.2 Tyrosine kinase receptors as functional markers and therapeutical targets of glioblastoma stem cells. Carla Boccaccio, Turin, Italy (slides not available)
L4.3 New drugs on the horizon targeting stem cells in NSCLC. Marie-Catherine Vozenin, Villejuif, France
Plenary session 5: DNA repair beyond PARP
L5.1 Educational introduction: DNA repair inhibitors; a medicinal chemist's perspective. Roger Griffin, Newcastle, UK
L5.2 Development of markers of DNA repair. Shivani Kummar, Bethesda, MD, USA
L5.3 Understanding failure of PARP inhibition in the clinic. Ruth Plummer, Newcastle, UK
L5.4 Inhibition of the DNA damage response kinase, ATR, as a promising anti-cancer approach. John Pollard, Abingdon, Oxfordshire, UK
L5.5 PARP inhibition and efficacy of topoisomerase I inhibitors. Yves Pommier, Bethesda, MD, USA
Plenary session 6: Combining targeted agents
L6.1 Educational introduction: How to optimize strategies for clinical development of combinations based on targeted Agents. Ahmad Awada, Brussels, Belgium
L6.2 Report from MDICT Task Force Meeting 2012: Early phase development of combinations of targeted agents. Lesley Seymour, Kingston, ON, Canada
L6.3 A phase 1 dose escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK inhibitor) in patients with advanced or metastatic solid tumors. Johann de Bono, Sutton, Surrey, UK (slides not available)
L6.4 Clinical interactions with combinations of novel agents. Lesley Seymour, Kingston, ON, Canada
L6.5 A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors - preliminary results. Michael Ong, Sutton, Surrey, UK
Plenary session 7: Targeted delivery of cancer therapy
L7.1 Nanotechnology for targeted drug delivery. Theresa Allen, Vancouver, Canada
L7.2 Antibody-drug conjugates: From the bench to the clinic. Ravi J. Chari, Waltham, MA, USA (slides not available)
L7.4 New formulations to improve drug delivery. Ahmad Awada, Brussels, Belgium
Plenary session 8: Miscellaneous drugs and targets (1)
L8.1 c-Met and met inhibitors. John Wright, Bethesda, MD, USA (slides not available)
L8.2 Mechanistic studies of cabozantinib, a MET-VEGFR2 inhibitor with anti-tumor activity in soft tissue and bone. Dana Aftab, South San Francisco, CA, USA (slides not available)
L8.3 Anti-CD19 BiTE blinatumomab induces high complete remission rate in adult patients with relapsed B-precursor ALL: updated results of an ongoing phase II trial. Nicola Gökbuget, Frankfurt, Germany (slides not available)
L8.4 Synthetic lethality screening for the development of rational combination therapy for leukemia. Christopher Porter, Aurora, CO, USA
L8.5 ARRY-614, a dual p38/Tie2 inhibitor for myelodysplastic syndromes: Overview of the Phase 1 experience. James Winkler, Boulder, CO, USA
Plenary session 9: Methodological and regulatory issues in the development of targeted agents
L9.1 Biomarker-driven trials in early drug development. Bernard Fine, South San Francisco, CA, USA (slides not available)
L9.2 Personalized therapy of colorectal cancer patients enrolled in Phase 1 trials with targeted agents based on molecular profiling of tumors. Rodrigo Dienstmann, Barcelona, Spain
L9.3 Clinical imaging in drug development. Otto Hoekstra, Amsterdam, The Netherlands
L9.4 Challenges of demonstrating overall survival (OS) benefit with new agents. Chris Twelves, Leeds, UK
Plenary session 10: Miscellaneous drugs and targets (2)
L10.1 Novel concepts in dendritic cell vaccination against cancer. Carl Figdor, Nijmegen, The Netherlands (slides not available)
L10.2 Biomarker analysis and final results of INT70/09 Phase II proof-of-concept study of pazopanib (PZP) in refractory urothelial cancer (UC). Andrea Necchi, Milan, Italy
Plenary session 11: Epigenetic targets
L11.1 Epigenetic targets: Established and in the pipeline. Susan Bates, Bethesda, MD, USA
L11.2 Targeting epigenetic changes in anti-leukemia therapy. Kevin Petrie, Sutton, Surrey, UK
L11.3 Combining a rexinoid with an EGFR inhibitor suppresses lung carcinogenesis independent of KRAS mutations in clinical trials and transgenic models. Konstantin Dragnev, Lebanon, NH, USA
L11.4 A genome-wide view of the co-associations of genes prone to chromosomal translocations. Cameron Osborne, Cambridge, UK (slides not available)
Plenary session 12: Miscellaneous drugs and targets (3)
L12.1 Discovery of a potent dual antagonist of both XIAP and cIAP1 using fragment based drug discovery. Gianni Chessari, Cambridge, UK
L12.2 Phase 1 study of PF-03446962, a human mAb against activin receptor like kinase 1 (ALK 1), involved in tumor angiogenesis. Cristina Noberasco, Milan, Italy
L12.3 Final results of a dose escalation study of HGS1036 (previously FP-1039), an FGF “trap” (FGFR1:Fc) in patients with advanced malignancies. Anthony Tolcher, San Antonio,TX, USA
L12.4 Inhibitors of Anaplastic Lymphoma Kinase: An update. Benjamin Solomon, Melbourne, Australia
L12.5 Efficient pharmacological prevention of the major side effects of cisplatin without affecting the antineoplastic efficacy in vivo. Jurgen Thomale, Essen, Germany
L12.6 Inhibition of mesenchymal stem cell related thromboxane synthase (TxS) and cyclooxygenase (COX)-1 prevents platinum-induced chemoresistance in vivo. Emile Voest, Utrecht, The Netherlands (slides not available)
L12.7 Mechanisms of resistance to anti-angiogenic kinase inhibitors. Henk Verheul, Amsterdam, The Netherlands
|
